Dr. So is a Specialist in Infectious Disease in private practice. His clinical services include hospital and clinic management of various infections, particularly in the travel-associated, the immunocompromised and the HIV-infected, the critical care and the resistant pathogens, emergency in infection.
He is currently President of The Hong Kong Society for Infectious Diseases, Board Member and immediate-past Chairman of Specialty Board in Infectious Disease, Hong Kong College of Physicians, Honorary Clinical Assistant Professor in the Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong. He has served in the Scientific Committee on Vaccine Preventable Diseases, under the Centre for Health Protection, Department of Health in Hong Kong from Jun 2004 to Jun 2013, with focus on influenza vaccination.
Besides, he worked for The Hong Kong Medical Association as member of Advisory Committee on Communicable Diseases and Public-Private Interface Vaccination Task Force from 2010 onwards. He has been elected as the Executive Committee Member of The Federation of Medical Societies of Hong Kong since Dec 2013.
After completion of undergraduate medical education in the University of Hong Kong, he pursued postgraduate study and training in Internal Medicine, Infectious Disease and Tropical Medicine in London and Birmingham of the United Kingdom and in Harvard Medical School of the USA. He worked in the Department of Medicine & Geriatrics, Princess Margaret Hospital and Infectious Disease Centre of Hospital Authority, Hong Kong as a general and infectious disease physician for over 20 years before private practice. He has been the Principal Investigator in Asian Network for Surveillance of Resistant Pathogens [ANSORP] in Hong Kong from 2000 to 2012 with research focus on antimicrobial resistance and therapeutics. His publications include topics on community acquired pneumonia, hospital acquired pneumonia, invasive pneumococcal infection, pneumococcal resistance, pneumococcal vaccine, Severe Acute Respiratory Syndrome (SARS) and SARS-Corona Virus, immunomodulatory therapy of chronic hepatitis B and traveller’s infection.